Commentary on 'Case for BJOG compliance with prospective trial registration by Duley, Leila et al.
 1
Commentary on case for BJOG compliance with 
prospective trial registration 
 
 
 
Lelia Duley1, Lisa Askie,2 Prathap Tharyan3 
 
1Nottingham Clinical Trials Unit, University of Nottingham; 2NHMRC Clinical Trials Centre, 
University of Sydney, Australia; 3South Asian Cochrane Centre, Christian Medical College, 
Vellore, India 
 
Prospective registration of clinical trials before enrolment of the first participant is an ethical 
and scientific imperative required by the International Committee of Medical Journal Editors 
(ICMJE) (De Angelis et al, Lancet 2004;364:911-2), the World Health Organization’s 
International Clinical Trials Registry Platform (WHO-ICTRP) and the revised World Medical 
Association’s Declaration of Helsinki.  Registering clinical trials reduces duplication of 
research and aids better identification of gaps in our knowledge, as when all research on a 
topic can be identified it is easier to know when a new study is not needed, as the question has 
already been answered; and if all research is identified it becomes easier to see where there 
are gaps, and so where new studies are needed. Prospective registration of clinical trials 
reduces publication bias and bias due to selective reporting of studies with equivocal or 
‘negative’ results, since studies are identified and registered before their results are known, 
and there is less likelihood that our understanding of research evidence is distorted by studies 
that have disappeared without a trace, or are slow to appear.  Prospective registration of trials 
additionally reduces bias due to selective reporting of outcomes that are ‘positive’ as 
outcomes are disclosed at registration and can be compared with published reports.  
Prospective registration thus contributes to less scientific misconduct, as failure to report 
research findings accurately and make them publicly available, is a betrayal of trust of the 
people who participated in that research, and can lead to harm in patient care.  Prospective 
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registration also makes it harder to fabricate research results, and can result in less scientific 
fraud (Abaid LN et al. Obstet Gynecol 2007;109:1434-7). 
 
Since its implementation in 2005, the ICMJE requirement for prospective trial registration has 
led to a rapid increase in the number of trials registered, but the quality and timing of 
registration still needs improvement. For example, in one recent survey just under half the 
trials published in high impact journals had been adequately registered, and trials published in 
general medical journals were more often properly registered than those published in 
speciality journals (Mathieu  et al, JAMA. 2009;302:977-984). Adequate registration for all 
trials requires the entire scientific community to endorse and adhere to the requirement for 
trial registration before the first participant is enrolled in a trial. Trial registration is not 
enough, registration needs to be prospective and provide adequate information about the study 
design to ensure that what is reported was what was intended. Submitting an unpublished 
study protocol along with the trial manuscript does not adequately fulfil the requirements of 
transparency, and does not eliminate doubts about reporting biases.  
 
To ensure publication of unbiased results the BJOG needs to ensure that its editors, authors 
and reviewers comply with its policy of requiring prospective trial registration. Trials which 
have failed to register prospectively should make their results publicly available, but should 
not be rewarded with publication in a mainstream journal such as BJOG. 
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